Chagas disease, caused by the parasite Trypanosoma cruzi, is a major neglected tropical disease in Latin America affecting over 6 million people. A test-of-cure to monitor treatment efficacy is desperately needed.
Using a novel multiplex immunoassay Multi-Cruzi, and in combination with a mathematical formula, InfYnity Biomarkers (France), DNDi, and the clinical team of J. Altcheh (Argentina) have now shown that the Multi-Cruzi assay can predict parasitological cure in T. cruzi-infected children substantially earlier than a conventional ELISA assay. The test emphasizes the concept of "serological signatures" and could represent a paradigm shift in forecasting serological outcomes after treatment in T. cruzi-infected individuals.
This work has now been published in the high impact journal “Lancet Infectious Diseases” and acknowledges the high-level of expertise developed by InfYnity in the field of infectious diseases and corresponding immune signatures.
For more details please follow the link below:
or download the article by clicking here
The Multi-Cruzi assay will be operational in the laboratory of J. Altcheh as of Q2-2021.
